Peer-influenced content. Sources you trust. No registration required. This is HCN.

The Journal of Clinical Investigation (JCI)Expansion, Persistence, and Efficacy of Donor Memory-like NK Cells Infused for Post-transplant Relapse

Responses to conventional donor lymphocyte infusion for post-allogeneic hematopoietic cell transplantation relapse are typically poor. Natural killer cell-based therapy is a promising modality to treat post-HCT relapse. This ongoing phase I trial of adoptively transferred cytokine induced memory-like (CIML) NK cells in patients with myeloid malignancies relapsed after haploidentical HCT saw a dynamic evolution of the activated CIML NK cell phenotype, superimposed on the natural variation in donor NK cell repertoires.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form